Drugs / TAPOTOCLAX
TAPOTOCLAX
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05209152 | Nov 2022 → Dec 2023 | chronic myelomonocytic leukemia, myelodysplastic syndrome | Amgen | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03797261 | Mar → Dec 2019 | acute myeloid leukemia, diffuse large B-cell lymphoma | AbbVie | Terminated | No outcome recorded |
| Phase 1 | NCT02675452 | Jun 2016 → May 2024 | acute myeloid leukemia, refractory plasma cell neoplasm | Amgen | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-09-12 | Amgen | Regulatory Amgen Highlights New Data From KYPROLIS® (carfilzomib) And Oncology Pipeline At IMW 2019 amgen.com ↗
In keeping with Amgen's commitment to patient safety, the AMG 176 Phase 1 trial ( NCT02675452 ) has been placed on a voluntary hold for new enrollment. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-09-12 | Amgen | Amgen Highlights New Data From KYPROLIS® (carfilzomib) And Oncology Pipeline At IMW 2019 amgen.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAPOTOCLAX | ChEMBL registry synonym — accepted as the source's own label CHEMBL4446378 ↗ |
| Known as | AMG 176 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03797261 ↗ |
| Known as | MCL-1 INHIBITOR AMG 176 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4446378 ↗ |
| Modality | Small molecule | — CHEMBL4446378 ↗ |
| Route | Intravenous | “AMG 176 administered IV” NCT02675452 ↗ |